At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
sunitinib malatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Sunitinib Malate (Sutent®; SU11248) in Patients With Intermediate-2 or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
In Brief
A Phase 2 clinical trial evaluating sunitinib malate for Chronic Myelomonocytic Leukemia and 3 related conditions. Completed, enrolled 10 participants across 4 sites in 2 countries.
Detailed Summary
This phase II trial is studying how well sunitinib works in treating patients with myelodysplastic syndromes or chronic myelomonocytic leukemia. Sunitinib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
First PostedMar 2007
Primary CompletionSep 2011
Study CompletionOct 2012
TodayJul 2026
First PostedMar 22, 2007
Enrollment StartFeb 1, 2007
Primary CompletionSep 1, 2011
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 19.3 years ago
Interventions
sunitinib malatedrug
Given orally